Thyroid Cancer Coverage from Every Angle

8-Week Relative Dose Intensity: Predictive of Outcomes With Lenvatinib in Thyroid Cancer?

By: Kayci Reyer
Posted: Tuesday, April 20, 2021

The administration of a target dose of lenvatinib at a maximum during the first 8 weeks of therapy may optimize survival outcomes in some patients with thyroid cancer, according to research presented in the Endocrine Journal. Though lenvatinib is a standard treatment of patients with radioiodine-refractory differentiated thyroid cancer, it is often associated with a high incidence rate of adverse events, particularly among Japanese patients.

“Administration of a sufficient dose of lenvatinib for the first 8 weeks is essential to achieve significant tumor shrinkage and prolong [progression-free survival], and targeting for ≥ 60% of [8 weeks’ relative dose intensity] is adequate,” concluded Shunji Takahashi, MD, of The Japanese Foundation for Cancer Research in Tokyo, and colleagues.

The retrospective analysis included 42 patients, 16 (38.1%) of whom were men, who had received more than 8 weeks of lenvatinib treatment between January 2012 and July 2020. A total of 38 patients (90.5%) had been diagnosed with papillary thyroid cancer, and 4 patients (9.5%) had been diagnosed with follicular thyroid cancer. Receiver operating characteristic curve analysis identified an optimal cutoff value of 60% for 8 weeks of relative dose intensity.

At a median follow-up of 16.4 months, the overall response rate was 73.8%. The disease control rate was 97.6%, the median progression-free survival was 20.2 months, and the median overall survival was 35.2 months. Compared with patients who received less than 60% relative dose intensity treatment, patients who received at least 60% relative dose intensity treatment experienced higher median progression-free survival (not reached vs. 11.0 months) and overall survival (not reached vs. 27.6 months). An 8-week course of relative dose intensity of lenvatinib of at least 60% was an independent prognostic factor for progression-free survival.

Disclosure: The study authors reported no conflicts of interest.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.